NRC FORM 374


U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 9 PAGES Amendment No. 38

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

	Licensee		In accordance with letter dated January 15,₌2019.	4. Expiration Date: November 30, 2024	
1. 2.	PharmaLogic Ltd. 1191 S. Brownell Road, Su Williston, VT 05495	uite 40	3. License number: 44-30124-01MD is amended in its entirety to read as follows:	5. Docket No.: 030-33449 Reference No.:	
6.	Byproduct, source, and/or special nuclear material	7. Chemical and/or physical	orm 8. Maximum amount that licen may possess at any one tim under this license		
Α.	Any byproduct material between Atomic Numbers 3 and 83 with Exceptions	A. Any Except Sealed Sou	rces A. 200 millicuries per source and 2 curies total	<ul> <li>A. For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.</li> </ul>	
В.	Fluorine-18	B. Any	B. 1 curie total	B. For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
С	Gallium-67	C. Any	C. 500 millicuries total	C. For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	



				License Number 44-30124-01MD			ISSION PAGE 3 OF 9 PAGES Docket or Reference Number 030-33449		
	MATERIALS LICENSE SUPPLEMENTARY SHEET		Amendment No. 38						
6.	Byproduct, source, and/or special nuclear material	7.	Chemical	and/or physical form	<b>8.</b>	Maximum amount that licensee may possess at any one time under this license	9.	Authorized use	
H.	Indium-111	H.	Any		H.	300 millicuries total	H.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
Ι.	lodine-123	I.	Any		<b>I.</b> 1997 - 1994 1997 - 1995 1997 - 1995 1997 - 1995	50 millicuries total	ł.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
J.	lodine-131	J.	Any		J.	2.5 curies total	J.	For preparation and distribution of radioactive drugs, including compounding of iodine-131, and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
K.	Xenon-133	K.	Any		<b>K.</b> 7	1.5 curies total	Κ.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	
L.	Samarium-153	L.	Any		L.	750 millicuries total	L.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.	

IRC FORM 374A			U.S. NUCLEA	R REGU	LATORY COMMISSION		PAGE 4 OF 9 PAGES
MATERIAL SUPPLEMEN			License Number 44-30124-01MD Amendment No. 38		Docket or Referen 030-33449	nce Nu	umber
<ol> <li>Byproduct, source, and/or special nuclear material</li> </ol>	7.	Chemical and	l/or physical form	8.	Maximum amount that licensee may possess at any one time under this license	9.	Authorized use
M. Thallium-201	Μ.	Any		Μ.	1 curie total	M.	For preparation and distribution of radioactive drugs and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients.
<ul> <li>N. Any byproduct mate permitted by 10 CFF 31.11</li> </ul>		Prepackage	d Kits	<b>N.</b>	50 millicuries total	N.	For redistribution to specific licensees or to general licensees in accordance with 10 CFR 31.11, provided the packaging and labeling remain unchanged.
O. Any byproduct mate authorized under 10 35.65		Ziegler Isoto Isotope Proc Model MED Series, RV-> EGLVM Seri Isotopes Ida BM06-37, BI BM06S Seri Isotopes, Inc and BM03-5 Scientific, In MED3400, a	ces (Eckert & pe Products dba lucts Laboratories, 3503, GF Type R (XX Series, and es; International ho, Inc./ Model M06E Series, and es; International c., Model BM03-57L 7A; North American c., Model MED3550, nd MED3402; cal Imaging formerly	0	500 millicuries total	Ο.	For use in calibration and checking of the licensee's instruments. For redistribution of sealed sources initially distributed by a manufacturer licensed in accordance to 10 CFR 32.74 to authorized recipients for medical and non-medical use.

NRC	FORM 374A			U.S. NUCLEAR	REGU	JLATORY COMMISSIO	)N		PAGE 5 OF 9 PAGES
	MATERIALS LIC			License Number 44-30124-01MD Amendment No. 38			cket or Reference 0-33449	ce Nu	umber
				-					
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and	/or physical form	8.	Maximum amount may possess at an junder this license		9.	Authorized use
Ρ.	Any byproduct material permitted in 10 CFR 35.400	P.	Brachytherap 1251; IsoAid IAI-125A; No Scientific, Ind	by, Model STM , LLC, Model rth American c., Model MED 3631 3; Theragenics, seed 200)	Ρ.	2 curies total		Ρ.	For redistribution of sealed sources initially distributed by a manufacturer licensed in accordance to 10 CFR 32.74 to authorized recipients for medical use. For redistribution of sealed sources that have been registered either with NRC under 10 CFR 32.210 or with an Agreement State and have been distributed in accordance with an NRC or Agreement State specific license authorizing distribution to persons specifically authorized by an NRC or Agreement State license to receive, possess and use the authorized device.
Q.	Any byproduct material between atomic numbers 2 & 83 with exceptions	Q.	Analytical Sa	imples	Q,	50 millicuries tota	al	Q.	For possession incident to the performance of tests for leakage on customers sealed sources.
R.	Uranium- depleted in Uranium-235	R.	Metal		<b>R.</b>	400 kilograms to	tal	R.	For shielding of molybdenum-99/technetium-99m generators .
S.	Germanium-68	S.	Any		S.	100 millicuries to	otal	S.	For use of the Eckert and Ziegler GalliaPharm™ generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies.
Τ.	Gallium-68	Т.	Any		Τ.	100 millicuries to	otal	Т.	For preparation and distribution of radioactive drugs in accordance with 10 CFR 32.72 and radiochemicals for non-medical use to authorized recipients.

NRC F	ORM 374A	U.S. NUCLEAR REGULATORY CO	OMMISSION	PAGE 6 OF 9 PAGES
	MATERIALS LICENSE	License Number 44-30124-01MD	Docket or Reference Number 030-33449	
	SUPPLEMENTARY SHEET	Amendment No. 38		
		CONDITIONS		
10.	Licensed material may be used or stored	d at the licensee's facilities located at	1191 S. Brownell Road, Suite 40	), Williston, Vermont.
11.	Licensed material shall only be used by,	or under the supervision of:		
	A. A pharmacist working or designated	as an authorized nuclear pharmacist	in accordance with 10 CFR 32.7	2(b)(2)(i) or (4).
	B. Authorized Nuclear Pharmacists:			Dhama D
	Reid Gadziala, Pharm.D.	Steven C. Green, R.Ph.	Charles and the second s	onymus, Pharm.D.
	Bynum L. Kimmons, R.Ph.	Joseph Olinzock, Pharm.D.	Glen Palmer	
	Ruth Mary Wetzel, R.Ph.	Zonker White, R.Ph.	. Anna K. Wie	IZDICKI, K.PN.
	C. Authorized Users working under the	supervision of an authorized nuclear	pharmacist:	
	James Cordonier, II, R.Ph.	David Ellis, R.Ph.	Kevin Hart, F	R.Ph.
	Garth Kistner, R.Ph.	Peteris Kruze, R.Ph.	Laurie Stallin	gs, R.Ph., BCNP
	Timothy Summers, R.Ph.	Dana Suttle, R.Ph.	Tamiko Ushio	o, R.Ph.
12.	The Radiation Safety Officer (RSO) for t	his license is Arow J. Hieronymus, Pl	narm.D.	
13.	In addition to the possession limits in Ite minimum limit specified in 10 CFR 30.35		•	erial to quantities below the
14.	This license does not authorize distribut	ion to persons exempt from licensing	•	

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION PAGE 7 OF 9 PAGES
MATERIALS LICENSE	License Number 44-30124-01MD	Docket or Reference Number 030-33449
SUPPLEMENTARY SHEET	Amendment No. 38	
registration issued by the U.S. Nuclea	ar Regulatory Commission under 10 CFI	not to exceed the intervals specified in the certificate of R 32.210 or by an Agreement State. In the absence of a amination at intervals not to exceed 6 months, or at such
registration issued by the U.S. Nuclea		been made within the intervals specified in the certificate of R 32.210 or by an Agreement State, prior to the transfer, a sted and the test results received.
		ontain only a radioactive gas; or the half-life of the isotope is or gamma-emitting material or not more than 10 microcuries
or transferred to another person, and	have not been tested within the require	sed. However, when they are removed from storage for use d leak test interval, they shall be tested before use or without being tested for leakage and/or contamination.
sample. If the test reveals the presen filed with the U.S. Nuclear Regulatory	ce of 185 becquerels (0.005 microcuries	0.005 microcuries) of radioactive material on the test s) or more of removable contamination, a report shall be R 30.50(c)(2), and the source shall be removed cordance with Commission regulations.
		and analysis, shall be performed by the licensee or other an Agreement State to perform such services.
G. Records of leak test results shall be k	kept in units of becquerels (microcuries)	and shall be maintained for 3 years.

NRC F	FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 8 OF 9 PAGES
	MATERIALS LICENSE	License Number 44-30124-01MD	Docket or Reference Number 030-33449	
	SUPPLEMENTARY SHEET	Amendment No. 38		
16.	Sealed sources or detector cells containi licensee, except as specifically authorize	•	d or sources removed from so	ource holders by the
17.	The licensee shall conduct a physical inv Commission, to account for all sealed so maintained for 3 years from the date of e numbers, and the date of the inventory.	urces and/or devices received and poss	essed under the license. Reco	ords of inventories shall be
18.	The licensee is authorized to hold radioa disposal in ordinary trash provided:	ctive material with a physical half-life of	less than or equal to 120 days	s for decay-in-storage before
	radiation labels shall be removed or c	e waste shall be surveyed at the container rposed shielding to determine that its rad obliterated, except for radiation labels or hey have been released from the license	dioactivity cannot be distinguis materials that are within cont	shed from background. All
		itted under this license condition shall be oduct material was placed in storage, the measured at the surface of each waste	eradionuclides disposed, the s	survey instrument used, the
19.	The licensee is authorized to retrieve, re- syringes and vials and their contents.	ceive and dispose of radioactive waste f	rom its customers, limited to ra	adiopharmacy-supplied
20.	Notwithstanding the requirements of 10 ( plan needed for the possession and use the commitments between the licensee a manufacturer/distributor in accordance w	of Ge-68/Ga-68 medical use generators and manufacturer (Eckert and Ziegler).	c (Eckert and Ziegler GalliaPha The licensee shall return the g	arm™ generators), based on enerators to the

NRC FORM 374A	U.S. NUCLEAR REGULA	PAGE 9 OF 9 PAGES	
MATERIALS LICENSE	License NumberDocket or Reference Number44-30124-01MD030-33449		
SUPPLEMENTARY SHEET	Amendment No. 38		

- 21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated November 16, 2012 [ML12342A318]
  - B. Letter dated January 18, 2013 [ML13024A274]
  - C. Letter dated October 30, 2014 [ML14321A541]
  - D. Letter dated November 7, 2014 [ML14323A351]
  - E. Letter dated January 20, 2015 [ML15048A172]
  - F. Letter received March 20, 2015 [ML15090A727]
  - G. Letter dated June 14, 2018 [ML18180A337]
  - H. Letter dated July 10, 2018 [ML18207A701]

## FOR THE U.S. NUCLEAR REGULATORY COMMISSION

nei Manyen By:

Janice Nguyen Region 1

Date: January 23, 2019